Literature DB >> 32016044

EGFR mutations in lung cancer: not all equal in the eyes of the immune system?

Kwun M Fong1,2, Brett G M Hughes2,3,4, Zarnie Lwin2,3,4, Ian A Yang1,2.   

Abstract

Entities:  

Year:  2019        PMID: 32016044      PMCID: PMC6976489          DOI: 10.21037/atm.2019.09.132

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


× No keyword cloud information.
  5 in total

1.  Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.

Authors:  Matthew D Hellmann; Tudor-Eliade Ciuleanu; Adam Pluzanski; Jong Seok Lee; Gregory A Otterson; Clarisse Audigier-Valette; Elisa Minenza; Helena Linardou; Sjaak Burgers; Pamela Salman; Hossein Borghaei; Suresh S Ramalingam; Julie Brahmer; Martin Reck; Kenneth J O'Byrne; William J Geese; George Green; Han Chang; Joseph Szustakowski; Prabhu Bhagavatheeswaran; Diane Healey; Yali Fu; Faith Nathan; Luis Paz-Ares
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

2.  Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.

Authors:  Leena Gandhi; Delvys Rodríguez-Abreu; Shirish Gadgeel; Emilio Esteban; Enriqueta Felip; Flávia De Angelis; Manuel Domine; Philip Clingan; Maximilian J Hochmair; Steven F Powell; Susanna Y-S Cheng; Helge G Bischoff; Nir Peled; Francesco Grossi; Ross R Jennens; Martin Reck; Rina Hui; Edward B Garon; Michael Boyer; Belén Rubio-Viqueira; Silvia Novello; Takayasu Kurata; Jhanelle E Gray; John Vida; Ziwen Wei; Jing Yang; Harry Raftopoulos; M Catherine Pietanza; Marina C Garassino
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

3.  EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China.

Authors:  Jianlin Xu; Bo Jin; Tianqing Chu; Xue Dong; Haitang Yang; Yanwei Zhang; Dan Wu; Yuqing Lou; Xueyan Zhang; Huiming Wang; Baohui Han
Journal:  Lung Cancer       Date:  2016-01-30       Impact factor: 5.705

4.  EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer.

Authors:  K Hastings; H A Yu; W Wei; F Sanchez-Vega; M DeVeaux; J Choi; H Rizvi; A Lisberg; A Truini; C A Lydon; Z Liu; B S Henick; A Wurtz; G Cai; A J Plodkowski; N M Long; D F Halpenny; J Killam; I Oliva; N Schultz; G J Riely; M E Arcila; M Ladanyi; D Zelterman; R S Herbst; S B Goldberg; M M Awad; E B Garon; S Gettinger; M D Hellmann; K Politi
Journal:  Ann Oncol       Date:  2019-08-01       Impact factor: 32.976

5.  Comprehensive molecular profiling of lung adenocarcinoma.

Authors: 
Journal:  Nature       Date:  2014-07-09       Impact factor: 49.962

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.